{"groups":[{"description":"E-Ld refers to the combination of Elotuzumab with Lenalidomide/Dexamethasone.","id":"FG000","title":"E-Ld"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"23"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"11"}],"type":"Other reasons"},{"reasons":[{"groupId":"FG000","numSubjects":"9"}],"type":"Administrative reason by Sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"9"}],"type":"Adverse Event unrelated to study drug"},{"reasons":[{"groupId":"FG000","numSubjects":"7"}],"type":"Study drug toxicity"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Maximum clinical benefit"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Subject request to discontinue treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Subject withdrew consent"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Lost to Follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"70"}],"type":"STARTED"},{"achievements":[{"comment":"Completed = Still on treatment","groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"70"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"84 participants were enrolled. 70 participants were randomized and treated. Reasons for non-randomization/non-treatment were 10 no longer met study criteria, 1 withdrew consent, and 3 due to other reasons."}